Stage III Pancreatic Cancer
73
1
7
52
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Published Results
15 trials with published results (21%)
Research Maturity
52 completed trials (71% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
11.0%
8 terminated out of 73 trials
86.7%
+0.2% vs benchmark
3%
2 trials in Phase 3/4
29%
15 of 52 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 52 completed trials
Clinical Trials (73)
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
Malnutrition Screening and Dietary Intervention to Improve Nutrition Outcomes in Patients With Unresectable Pancreatic Cancer
Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy
Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer
A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer
Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer
Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors